Evidence map›Paper›PMID 39808222›Full record

ArticleScience China. Life sciences2025

FSD1 inhibits glioblastoma diffuse infiltration through restriction of HDAC6-mediated microtubule deacetylation.

Dake Xiao, Haowen Ran, Lishu Chen, Yuanyuan Li, Yan Cai, Songyang Zhang, Qinghui Qi, Huiran Wu, Cheng Zhang, Shuailiang Cao and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Science China. Life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Dake Xiao *Nanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Haowen Ran *Nanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Lishu ChenNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Yuanyuan LiNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Yan CaiNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Songyang ZhangNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Qinghui QiNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Huiran WuNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Cheng ZhangNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Shuailiang CaoNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Lanjuan MiNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Haohao HuangNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Ji QiDepartment of Neurosurgery, Beijing Fengtai Hospital, Beijing, 100070, China.
Qiuying HanNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Haiqing TuNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Huiyan LiNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Tao ZhouNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China.
Fangye LiDepartment of Neurosurgery, First Medical Center of PLA General Hospital, Beijing, 100853, China. leefangye@126.com.
Ailing LiNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China. alli@ncba.ac.cn.
Jianghong ManNanhu Laboratory, National Center of Biomedical Analysis, Beijing, 100850, China. jhman@ncba.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The infiltration of glioblastoma multiforme (GBM) is predominantly characterized by diffuse spread, contributing significantly to therapy resistance and recurrence of GBM. In this study, we reveal that microtubule deacetylation, mediated through the downregulation of fibronectin type III and SPRY domain-containing 1 (FSD1), plays a pivotal role in promoting GBM diffuse infiltration. FSD1 directly interacts with histone deacetylase 6 (HDAC6) at its second catalytic domain, thereby impeding its deacetylase activity on α-tubulin and preventing microtubule deacetylation and depolymerization. This inhibitory interaction is disrupted upon phosphorylation of FSD1 at its Ser317 and Ser324 residues by activated CDK5, leading to FSD1 dissociation from microtubules and facilitating HDAC6-mediated α-tubulin deacetylation. Furthermore, increased expression of FSD1 or interference with FSD1 phosphorylation reduces microtubule deacetylation, suppresses invasion of GBM stem cells, and ultimately mitigates tumor infiltration in orthotopic GBM xenografts. Importantly, GBM tissues exhibit diminished levels of FSD1 expression, correlating with microtubule deacetylation and unfavorable clinical outcomes in GBM patients. These findings elucidate the mechanistic involvement of microtubule deacetylation in driving GBM cell invasion and offer potential avenues for managing GBM infiltration.

Indexed as

Brain NeoplasmsGlioblastomaHistone Deacetylase 6MicrotubulesAcetylationAnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceMice, NudeNeoplasm InvasivenessPhosphorylationTubulinHDAC6 protein, humanHistone Deacetylase 6TubulinFSD1glioblastoma multiforme (GBM)HDAC6invasionmicrotubule deacetylation

Identifiers

PMID39808222

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.